- Home
- GNRC vs ABVX Comparison
GNRC vs ABVX Comparison
Compare GNRC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNRC | ABVX |
|---|---|---|
| Founded | 1959 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 9.2B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNRC | ABVX |
|---|---|---|
| Price | $161.40 | $117.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 11 |
| Target Price | ★ $190.72 | $130.09 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 02-11-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.08 | N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $4,352,444,000.00 | $6,231,374.00 |
| Revenue This Year | $1.66 | $6.80 |
| Revenue Next Year | $10.72 | N/A |
| P/E Ratio | $30.83 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $99.50 | $4.77 |
| 52 Week High | $203.25 | $148.83 |
Technical Indicators
Market Signals| Indicator | GNRC | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 61.67 | 46.37 |
| Support Level | $153.00 | $113.40 |
| Resistance Level | $163.53 | $130.13 |
| Average True Range (ATR) | 5.21 | 8.88 |
| MACD | 2.50 | -1.76 |
| Stochastic Oscillator | 78.44 | 28.43 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.